Author(s)
Dr. Sayantan Patra, Dr. Reetoja Das, Dr. Soumya Suvra Patra, Smt. Sima Patra (Bhandari)
- Manuscript ID: 140333
- Volume: 2
- Issue: 6
- Pages: 375–382
Subject Area: Other
Abstract
I-125 seed implantation is a form of low-dose-rate (LDR) brachytherapy that has become a cornerstone of interventional oncology. Utilizing the radioactive decay of Iodine-125, these seeds provide highly localized radiation (0.7 cGy/hour) that induces DNA damage and inhibits angiogenesis within a clinical target volume. This review explores the dosimetry required for successful ablation, patient selection criteria, and specific use case scenarios ranging from standalone prostate cancer treatment to novel combination therapies and seed-integrated stents. By focusing on localized energy deposition, I-125 implantation minimizes collateral damage to healthy tissues, offering a viable alternative for patients with recurrent tumors or those ineligible for major surgery.